Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $10.95M rose 184.4% year over year, ahead of the +72.6% change in trailing-twelve-month research & development. Sequentially, it rose 39.2% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +184.4% holds above the trailing-twelve-month pace of +72.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.95M+39.2% QoQ
Last fiscal yearDec 2025
$29.51M+83.6% YoY
LTMMar 2026
$27.18M+72.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+184.4%——
1 year+83.6%——
3-year CAGR+29.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

Mixed currencies · from the income statement

Latest · FY2025
29.51M USD
Year-over-year change
+83.6%

Research & Development vs competitors

How EPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +72.6% is the 2nd highest of 9, against a peer median of +35.0%.
  • Over three fiscal years its annual growth of +29.4% compares with a peer median of +11.7%.
EPRX Competitors
Research & Development for EPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$62.82M USD+25.5%-7.1%3539.3%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$60.48M USD+28.2%+38.4%184.8%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$57.75M USD+141.5%+89.7%—
TARAProtara Therapeutics, Inc.LTM Mar 2026$46.96M USD+41.8%+36.4%—
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$40.3M USD-12.6%+4.1%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.18M USD+72.6%+29.4%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$23.16M USD+47.2%-19.1%—
MDWDMediWound Ltd.LTM Mar 2026$16.62M USD+61.4%+12.0%114.8%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$3.93M USD———
Peer median (excluding EPRX) —+35.0%+11.7%1024.9%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue112.38K00163.47K331.89K
Gross Profit(112.38K)00(163.47K)(331.89K)
Gross Margin—————
Research & Development7.59M13.63M15.33M16.07M29.51M
Selling, General & Admin6.97M3.99M5.63M10.92M17.1M
Operating Expenses14.65M17.62M20.97M26.99M53.33M
Depreciation & Amortization87.47K147.89K117.1K171.6K331.89K
EBITDA(17.22M)(17.86M)(20.78M)(24.95M)(53.33M)
EBITDA Margin—————
Operating Income(14.65M)(17.62M)(20.97M)(26.99M)(53.66M)
Operating Margin—————
Interest Income51.55K431.8K649.75K1.16M1.41M
Interest Expense1.02M982.86K881.05K603.17K0
Other Income / Expenses(3.68M)(1.37M)(814.93K)1.26M(212.94K)
Income Before Tax(18.33M)(18.99M)(21.78M)(25.73M)(53.87M)
Pre-Tax Margin—————
Income Tax Expense0027.42K1.8K26.65K
Net Income(18.03M)(18.49M)(21.25M)(25.49M)(53.86M)
Net Margin—————
EPS (Basic)(1.63)(0.96)(0.88)(0.76)(1.05)
EPS (Diluted)(1.63)(0.96)(0.88)(0.76)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.